Overview

Safety, Feasibility, and Tolerability of Sulforaphane in Children With Chronic Kidney Disease

Status:
Not yet recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
This purpose of this study is to investigate potential new therapeutics in pediatric chronic kidney disease (CKD). The specific aims are to identify safe dosing and tolerability of sulforaphane (SFN) supplementation in children with moderate and advanced CKD. Secondary objectives will include preliminary exploration of changes in oxidative and inflammatory biomarkers in response to SFN supplementation in this population.
Phase:
Phase 2
Details
Lead Sponsor:
University of Rochester
Collaborator:
Renal Research Institute
Treatments:
Sulforaphane